Metrics to compare | LTUS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLTUSPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | 7.3x | −0.2x | |
PEG Ratio | 0.00 | −0.18 | 0.00 | |
Price/Book | 0.0x | 1.8x | 2.6x | |
Price / LTM Sales | 0.0x | 1.4x | 2.7x | |
Upside (Analyst Target) | - | 142.1% | 66.0% | |
Fair Value Upside | Unlock | 28.4% | 10.8% | Unlock |
Lotus Pharmaceuticals, Inc. operates as a high-conviction pharmaceutical and healthcare investment and industry integration company. The company focuses on building a asset portfolio across the global pharmaceutical and healthcare value chain through global strategic investments, mergers and acquisitions, and industry consolidation. It seeks opportunities across pharmaceuticals and biologics, biopharmaceutical services (CRO/CDMO), oncology pharmaceuticals, medical institutions, medical devices and diagnostics, digital health, smart elderly care, AI-powered healthcare technologies, internet-based medical services, and new-technology medical aesthetics. The company was formerly known as S.E. Asia Trading, Inc. and changed its name to Lotus Pharmaceuticals, Inc. in December 2006. Lotus Pharmaceuticals, Inc. is based in Irvine, California.